Skip to main content
. 2020 Jul 4;21(13):4767. doi: 10.3390/ijms21134767
3DCRT three-dimensional conformation radiation therapy
5-FU 5-fluorouracil
ABCG2 ATP-binding cassette super-family G member 2
AKT protein kinase B
Arg arginase
ATM ataxia telangiectasia mutated
ATP adenosine triphosphate
BED biological equivalent dose
BRCA2 breast cancer type 2 susceptibility protein
BR-PDAC borderline resectable PDAC
CAF cancer associated fibroblast
CCL2 chemokine ligand 2
CCR2 C-C chemokine receptor type 2
CDK4/6 cyclin-dependent kinase 4 and 6
CDKN2A cyclin-dependent kinase inhibitor 2A
cGAS cyclic GMP-AMP synthase
CRT chemoradiotherapy
CSC cancer stem cell
CSF1 colony-stimulating factor
CSF1R colony-stimulating factor 1 receptor
CT chemotherapy
CTLA4 cytotoxic T-lymphocyte associated protein 4
CXCR4 C-X-C motif chemokine receptor 4
DAMPs damage associated molecular patterns
DC denditric cell
EGFR epidermal growth factor receptor
EMT epithelial to mesenchymal transition
EORTC European organisation for research and treatment of cancer
ERK mitogen-activated protein kinase 1
ESPAC European study group for pancreatic cancer
EV extracellular vesicle
FLASH RT ultrahigh dose-rate radiation therapy
GIST gastrointestinal study group
HIF-1α hypoxia inducible factor 1
HMGB-1 high mobility group box 1
HR homologous recombination
ICD immunogenic cell death
IFN-γ interferon-γ
IMRT intensity modulated radiation therapy
iNOS inducible nitric oxide synthase
KRAS kirsten rat sarcoma
LA-PDAC locally advanced PDAC
LET linear energy transfer
LPS lipopolysaccharide
MDSC myeloid-derived suppressor cells
MEK mitogen-activated protein kinase kinase
MHC 1 major histocompatibility complex class 1
mTOR mammalian target of rapamycin
nab-paclitaxel nanoparticle-bound paclitaxel
NF-κB nuclear factor kappa B
NHEJ non homologous end joining
NRF2 nuclear factor erythroid 2-related factor 2
OAR organ at risk
OS overall survival
PARP poly(ADP-ribose) polymerase
PDAC pancreatic ductal adenocarcinoma
PD1 programmed cell death 1
PDK1 pyruvate dehydrogenase kinase 1
PD-L1 programmed cell death ligand 1
PDX patient-derived xenograft
PI3K phosphatidylinositol 3-kinase
POLO pancreas cancer olaparib ongoing
PREOPANC preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer
PRODIGE trial comparing adjuvant chemotherapy with gemcitabine versus mfolfirinox to treat resected pancreatic adenocarcinoma
PT proton therapy
RAF rapidly accelerated fibrosarcoma
RAS rat sarcoma
RBE relative biological effectiveness
ROS reactive oxygen species
R-PDAC resectable PDAC
RT radiotherapy
RTOG radiation therapy oncology group
SBRT stereotactic body radiation therapy
SDF-1 stromal derived factor 1
SMAD4 mothers against decapentaplegic homolog 4
SMART stereotactic magnetic resonance guide adaption radiation therapy
SPArc continuous spot-scanning protons arc
STING stimulator of interferon genes
TAM tumour-associated macrophages
TGFβ transforming growth factor beta
TIL tumour infiltrating lymphocytes
TNF tumour necrosis factor
TRAIL TNF-related apoptosis-inducing ligand
Trex1 three prime repair exonuclease 1
UPR unfolded protein response
VEGF vascular endothelial growth factor
Wnt wingless-integration-1
ZEB zinc finger E-box binding homeobox